Second Plague Death Confirmed in Colorado
The Pueblo City-County Health Department has confirmed the death of an adult due to the plague.
The Pueblo City-County Health Department has confirmed the death of an adult due to the plague.
The Food and Drug Administration (FDA) granted Breakthrough Therapy designation to Xalkori (crizotinib; Pfizer) for the treatment of patients with ROS1-positive non-small cell lung cancer (NSCLC).
Sanofi Pasteur announced that Sklice (ivermectin) Lotion, 0.5%, is now available for the treatment of head lice in patients 6 months of age and older.
Acella Pharmaceuticals announced that the FDA has approved Gabapentin oral solution 250mg/5mL, the generic equivalent of Pfizer’s Neurontin oral solution 250mg/5mL.
Anthera Pharmaceuticals announced the completion of dosing in its Phase 2b study of blisbimod for patients with systemic lupus erythematosus.
The FDA announced that long-acting beta agonists (LABAs) should never be used alone in the treatment of asthma.
Nereus Pharmaceuticals announced positive interim results from a randomized Phase 2 clinical trial evaluating the vascular disrupting agent (VDA) plinabulin (NPI-2358) in combination with standard chemotherapy (docetaxel) in patients with advanced non-small cell lung cancer (NSCLC).
Barr Laboratories has issued a voluntary recall of dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate (mixed salts of a single entity amphetamine product) 20mg tablets, 100 count bottles, Lot# 311756, distributed between June 11, 2009 and June 16, 2009.
The FDA has approved Orexo’s Edluar (zolpidem, [formerly known as Sublinox]), an imidazopyridine hypnotic, for the short-term treatment of insomnia characterized by difficulties with sleep initiation.